FULL-YEAR 2018 SALES WORLDWIDE

$30.6 billion

+7.3% on organic basis

STRENGTH PERFORMANCE IN CORE BUSINESS SEGMENTS

+6.7% DIAGNOSTICS
+5.2% NUTRITION
+9.1% MEDICAL DEVICES
+7.0% ESTABLISHED PHARMACEUTICALS

FULL-YEAR 2019 GUIDANCE

$3.15 to $3.25

ADJUSTED EPS

MIDPOINT REFLECTS DOUBLE DIGIT GROWTH

DELIVERING IMPRESSIVE GROWTH THROUGH A STRONG PRODUCT PIPELINE

- Freestyle Libre® system: Our revolutionary sensor-based continuous glucose monitoring system is one of the world's fastest-growing medical devices — with more than 1 million users.
- Alinity™: Our new suite of diagnostic systems offers leapfrog-level innovation to provide ease of use, greater flexibility and a smaller laboratory footprint.
- Structural Heart portfolio: Our minimally invasive solutions span the spectrum of heart valve disease and congenital heart defects.

CREATING SHAREHOLDER VALUE

14.3% Dividend increase for 2019 payouts

$2B returned to shareholders in the form of dividends in 2018

REPAID MORE THAN $8B of debt, enhancing our strategic flexibility

FORWARD-LOOKING STATEMENTS

Some statements in this communication may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended December 31, 2017, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.